# EDGAR Filing Document

**Accession Number:** 0001720446
**File Stem:** 0001104659-25-073254
**Filing Date:** 2025-8
**Character Count:** 34577
**Document Hash:** 2ba4423a7653e6b58289473338c2de46
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-073254.hdr.sgml**: 20250804

**ACCESSION NUMBER**: 0001104659-25-073254

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250804

**FILED AS OF DATE**: 20250804

**DATE AS OF CHANGE**: 20250804

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Zepp Health Corp
- **CENTRAL INDEX KEY:** 0001720446
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTRONIC COMPUTERS [3571]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38369
- **FILM NUMBER:** 251177862

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** BUILDING B2, ZHONG'AN CHUANGGU
- **STREET 2:** TECHNOLOGY PARK NO.900 WANGJIANG WEST RD
- **CITY:** HEFEI
- **PROVINCE COUNTRY:** F4
- **ZIP:** 230088
- **BUSINESS PHONE:** 86551-65837200

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** BUILDING B2, ZHONG'AN CHUANGGU
- **STREET 2:** TECHNOLOGY PARK NO.900 WANGJIANG WEST RD
- **CITY:** HEFEI
- **PROVINCE COUNTRY:** F4
- **ZIP:** 230088

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Huami Corp
- **DATE OF NAME CHANGE:** 20171023

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16 UNDER**

**THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of August 2025**

**Commission File Number: 001-38369**

**Zepp Health Corporation**

(Registrant's Name)

**Edisonweg 44 – B08, 4207 HG Gorinchem, The Netherlands**

**(Address of principal executive offices)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ⌧ Form 40-F ◻

**Exhibit Index**

[Exhibit 99.1 – Press Release](tm2522459d1_ex99-1.htm)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| **Zepp Health Corporation** | **Zepp Health Corporation** |
| By: | /s/ Leon Deng |
| Name: | Leon Deng |
| Title: | Chief Financial Officer |

---

Date: August 4, 2025

## Exhibit 99.1

**Exhibit 99.1**

**Zepp Health Corporation Reports** **Second Quarter 2025 Unaudited Financial Results**

MILPITAS, Calif., August 3, 2025 /PRNewswire/ -- Zepp Health Corporation ("Zepp" or the "Company") (NYSE: ZEPP) today announced its unaudited financial results for the second quarter of 2025.

Second Quarter 2025 Financial and Operating Highlights:

· Revenue reached US$59.4 million, representing
46.2% year-over-year growth and surpassing the high end of the guidance range announced previously.

· GAAP and adjusted net loss <sup>1</sup> was US$7.7 million and US$6.16 million, which narrowed by 28.6% and 30.2% compared with the second quarter of 2024.

· For the third quarter of 2025, management currently
expects net revenues to be between US$72.0 million and US$76.0 million, which would represent a year-over-year increase of approximately
70% to 79%.

· New product debut: Amazfit Balance 2 and Amazfit
Helio Strap.

· Welcomed NFL first-tier athlete and Pro Bowl running back Derrick Henry and
Ultra Runner Rod Farvard to our athlete's family.

Mr. Wang "Wayne" Huang, Chairman and CEO of Zepp, commented, "In the second quarter of 2025, we are pleased to report 46.2% year-over-year revenue growth—driven entirely by Amazfit products—marking our first overall revenue growth since 2021. Coupled with continued improvement in our bottom line, this achievement underscores the effectiveness of our strategic pivot to Amazfit-branded ecosystem in recent years. More importantly, it serves as a compelling testament to the enhanced global brand awareness of Amazfit brand. Additionally, our diversified global supply chain has successfully mitigated a big part of the tariff risks as projected, and the operational progress we made in the first half of the year has offset majority of these headwinds through volume growth and cost efficiencies."

<sup>1</sup> Adjusted net income/(loss) attributable to Zepp Health Corporation represents net income/(loss) excluding (i) share-based compensation expenses, (ii) amortization of intangible assets resulting from acquisitions and business cooperation agreements, (iii) gain/(loss) from fair value change of long-term investment, (iv) impairment loss from long-term investments, (v) income/(loss) from equity method investments, and (vi) tax effects of the above non-GAAP adjustments. See "Reconciliation of GAAP and non-GAAP results" at the end of this press release.

"We continue to foster a strong Amazfit Athletes team, now boasting over ten sports stars. This quarter, we're excited to welcome Derrick Henry—NFL standout and Rob Farvard, Ultra Runner—to our growing roaster of Amazfit athlete ambassadors. They will work closely with us on product testing, athlete led storytelling and grassroots community events to help bring the brand endurance focused innovations to life. Complementing this, our targeted, multi-layered global marketing campaigns across YouTube, TikTok, and Instagram have formed a powerful "marketing ecosystem." Amazon Prime Day recently served as a compelling testament to the impact of these efforts: in the U.S., Amazfit ranked as the second most improved wearables brand year-over-year; in EMEA, Prime Day sales surged approximately 60% versus the 2024 event."

"This quarter is just the beginning of our upward trajectory. With a robust pipeline of innovations, we're well-equipped to build on this momentum, driving sustained growth and value through the second half of 2025 and beyond," Mr. Huang concluded.

Mr. Leon Deng, Zepp's Chief Financial Officer, added, "In the second quarter of 2025, we exceeded the high end of our revenue guidance, driven by strong demand for our Amazfit Bip 6, Active 2, and T-Rex 3 models. The June launches of the Helio Strap and Balance 2 also contributed positively, together with a strong second half product pipeline, positioning us for a strong second half. We delivered our best-ever Prime Day performance in a relative soft macro environment —further evidence of our brand's growing strength and product appeal.

Gross margin came in at 36.2%, consistent with the prior quarter. GAAP and adjusted operating expenses<sup>2</sup> totaled US$27.6 million and US$26.4 million, down from US$32.7 million and US$31.5 million in the first quarter of 2025 and aligned towards our quarterly run rate target. Concurrently, we remain committed to investing in R&D and marketing activities to ensure our long-term competitiveness.

<sup>2</sup> Adjusted operating expenses represent operating expenses excluding (i) share-based compensation expenses and (ii) amortization of intangible assets resulting from acquisitions and business cooperation agreements. See "Reconciliation of GAAP and non-GAAP results" at the end of this press release.

GAAP and adjusted operating loss<sup>3</sup> narrowed to approximately US$6.1 million and US$4.9 million, marking a meaningful improvement versus last year and previous quarter.

We ended the quarter with US$95.3 million in cash. Inventory increased as the company strategically increased stock in key product lines to prepare for our upcoming product launches and offset potential tariff impacts, while our capital structure remained stable—with long-term debt accounting for the significant part of obligations. Our 2025 share repurchase program remains active, underscoring confidence in our long-term outlook.

For the third quarter, we project revenue of US$72.0 million to US$76.0 million, representing 70% to 79% year-over-year growth. This forecast reflects our strong execution and sustained product momentum, particularly the positive market reception of our recent new launches."

<sup>3</sup> Adjusted operating income/(loss) represents operating income/(loss) excluding: (i) share-based compensation expenses and (ii) amortization of intangible assets resulting from acquisitions and business cooperation agreements. See "Reconciliation of GAAP and non-GAAP results" at the end of this press release.

**Second Quarter of 2025 Financial Results**

**Revenues**

Revenues for the second quarter of 2025 reached US$59.4 million, an increase by 46.2% and 54.2% from the second quarter of 2024 and first quarter of 2025, respectively, marking a return to year-over-year growth since the second quarter of 2021. The increase was mainly driven by the popularity of our Amazfit Bip 6 and Active 2 ranges, as well as the T-Rex 3 and newly launched products namely Amazfit Helio Strap and Balance 2 in June 2025. Looking at the third quarter of 2025, we are expecting the Amazfit-branded sales continue to grow.

**Gross Margin**

Gross margin in the second quarter of 2025 was 36.2%, which was in line with first quarter of 2025 but worse than the second quarter of 2024. The year-over-year gross margin decline is due to a higher revenue proportion of relative lower-margin entry-level products namely Amazfit Bip 6 and Active 2 smartwatches and the clearance of older mid-range Balance 1 products at reduced prices to prepare for the new Balance 2 range launches. Gross margin remained stable sequentially. As we are entering the third quarter of 2025, with a full quarter of Balance 2 and new products launch, we expect the positive trend in gross margin to continue.

**Research and Development Expenses**

Research and development expenses in the second quarter of 2025 were US$11.2 million, an increase by 3.1% year-over-year. The increase was a result from our investment in new technologies, including AI, to maintain our competitive edge against our peers. Furthermore, our pipeline is robust with a series of cutting-edge products set to launch. At the same time, we focused on refined research and development approaches, as we consistently evaluated resource efficiency to optimize return on investment and productivity.

**Selling and Marketing Expenses**

Selling and marketing expenses in the second quarter of 2025 were US$12.1 million, an increase by 14.2% year-over-year, and decrease of 12.9% quarter-over-quarter. The year-over-year increase was primarily due to the promotional campaigns to build brand recognition and drive sales growth. The quarter-over-quarter decrease was primarily due to the absence of large-scale physical launch events, such as the CES exhibition held in the first quarter of 2025, however, we continue to invest in selling and marketing expenses and signed a few more renowned athletes to expand of our Amazfit Athletes team to build brand recognition. At the same time, we consistently pushed on retail profitability and channel mix improvement, which included meticulous refinement of our retail channels and strategic staffing arrangements across sales regions. We are committed to investing efficiently in marketing and branding to ensure our sustainable growth.

**General and Administrative Expenses**

General and administrative expenses were US$4.4 million in the second quarter of 2025, compared with US$4.9 million in the same period of 2024, a decrease by 9.7% year-over-year. We continue to streamline on our general and administrative expenses.

**Operating Expenses**

Total operating expenses for the second quarter of 2025 were US$27.6 million, an increase by 5.2% year-over-year. Adjusted operating expenses, which exclude share-based compensation and amortization of intangible assets resulting from acquisitions and business cooperation agreements, were US$26.4 million, compared with US$24.8 million in the same period of 2024. The increase was due to continues investment in cutting-edge technologies and new products innovation, as well as marketing and brand building initiatives. We will maintain our cost-conscious approach and remain committed to investing in R&D and marketing activities to ensure our long-term competitiveness.

**Operating Income/(Loss)**

Operating loss for the second quarter of 2025 was US$6.1 million, which was narrowed by 38.2% compared with the second quarter of 2024.

**Net Income/(Loss)**

Net loss attributable to Zepp Health Corporation for the second quarter of 2025 was US$7.7 million, compared to net loss of US$10.8 million in the second quarter of 2024. Adjusted net loss attributable to Zepp Health Corporation was US$6.16 million, compared to adjusted net loss of US$8.8 million in the second quarter of 2024.

**Liquidity and Capital Resources**

As of June 30, 2025, the Company had cash and cash equivalents and restricted cash of US$95.3 million, compared with US$103.8 million of cash balance as of March 31, 2025. This cash position provides ample runway for the Company to invest and seize potential market opportunities. In the third quarter of 2025, we expect our overall cash position to grow from its current levels.

The Company continued to manage its working capital and inventory efficiently and recorded inventory of US$79.9 million as of June 30, 2025. Inventory increased as the Company strategically increased stock in key product lines to prepare for the upcoming product launches and offset potential tariff impacts. The Company improved it management of accounts receivable collections and accounts payable payment terms. The Company will continue to manage working capital tightly.

Starting the first quarter of 2023, we have initiated the retirement of our short/long-term debt portfolio. As of the second quarter of 2025, the Company has retired a total of US$68.0 million of debt since early 2023, the overall long-term and short-term debt levels remain the same between the end of the second quarter and first quarter of 2025. As our operating cash flow continues to strengthen, we will continue to optimize the capital structure for the Company.

**Share Repurchase Program Update**

The Company announced in its third quarter 2021 earnings release that the board had authorized a share repurchase program of up to US$20 million through November 2022. On November 21, 2022, the board authorized a 12-month extension of the Company's share repurchase program. On November 20, 2023, the board further authorized the Company to extend its share repurchase program for another 12 months. On November 18, 2024, the board further authorized the Company to extend its share repurchase program for another 24 months. Pursuant to the extended share repurchase program, the Company may repurchase its shares in the form of ADSs and/or ordinary shares through November 2026 with an aggregate value equal to the remaining balance under the share repurchase program. As of June 30, 2025, the Company had used US$16.0 million to repurchase approximately 2.2 million ADSs. The Company expects to fund the repurchases under the extended share repurchase program out of its existing cash balance.

**Outlook**

For the third quarter of 2025, the Company's management currently expects net revenues to be between US$72.0 million and US$76.0 million, which would represent an increase of approximately 70% to 79% from US$42.5 million in the third quarter of 2024.

This outlook is based on current market conditions and reflects the Company's current and preliminary estimates of market, operating conditions and customer demand, which are all subject to change.

**Conference Call**

The Company's management team will hold a conference call at 9:30 p.m. Eastern Time on Sunday, August 3, 2025 to discuss financial results and answer questions from investors and analysts. Listeners may access the call by dialing:

---

| | |
|:---|:---|
| US (Toll Free): | +1-888-346-8982 |
| International: | +1-412-902-4272 |
| Mainland China (Toll Free): | 400-120-1203 |
| Hong Kong (Toll Free): | 800-905-945 |
| Hong Kong: | +852-3018-4992 |

---

Participants should dial in at least 10 minutes before the scheduled start time and ask to be connected to the call for "Zepp Health Corporation".

Additionally, a live and archived webcast of the conference call will be available at http://ir.zepp.com.

A telephone replay will be available one hour after the call until August 10, 2025 by dialing:

US Toll Free: +1-877-344-7529 <br> International: +1-412-317-0088 <br> Replay Passcode: 6611957

**A** **bout Zepp Health Corporation**

**Use of Non-GAAP Measures**

We use adjusted net income/(loss), a non-GAAP financial measure, in evaluating our operating results and for financial and operational decision-making purposes. **Adjusted operating expenses** represent operating expenses excluding (i) share-based compensation expenses and (ii) amortization of intangible assets resulting from acquisitions and business cooperation agreements. **Adjusted operating income/(loss)** represents operating income/(loss) excluding: (i) share-based compensation expenses and (ii) amortization of intangible assets resulting from acquisitions and business cooperation agreements. **Adjusted EBIT** represents net income/(loss) excluding (i) share-based compensation expenses, (ii) amortization of intangible assets resulting from acquisitions and business cooperation agreements, (iii) gain/(loss) from fair value change of long-term investment, (iv) impairment loss from long-term investments, (v) income/(loss) from equity method investments, (vi) income tax (benefit)/expense, and (vii) interest income and interest expense. **Adjusted net income/(loss) attributable to Zepp Health Corporation** is a non-GAAP measure, which excludes (i) share-based compensation expenses, (ii) amortization of intangible assets resulting from acquisitions and business cooperation agreements, (iii) gain/(loss) from fair value change of long-term investment, (iv) impairment loss from long-term investments, (v) income/(loss) from equity method investments, and (vi) tax effects of the above non-GAAP adjustments, and is used as the numerator in computation of adjusted net income/(loss) per share and per ADS attributable to Zepp Health Corporation.

We believe that adjusted EBIT and adjusted net income/(loss) attributable to Zepp Health Corporation help identify underlying trends in our business that could otherwise be distorted by the effect of certain expenses that we include in net income/(loss) and net income/(loss) attributable to Zepp Health Corporation. We believe adjusted EBIT and adjusted net income/(loss) attributable to Zepp Health Corporation provides useful information about our operating results, enhances the overall understanding of our past performance and future prospects and allows for greater visibility with respect to key metrics used by our management in its financial and operational decision-making.

Adjusted EBIT and adjusted net income/(loss) attributable to Zepp Health Corporation, should not be considered in isolation or construed as an alternative to net income/(loss), basic and diluted net income/(loss) per share and per ADS attributable to Zepp Health Corporation or any other measure of performance or as an indicator of our operating performance. Investors are encouraged to review the historical non-GAAP financial measures to the most directly comparable GAAP measures. Adjusted EBIT and adjusted net income/(loss) attributable to ordinary shareholders, presented here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to our data. We encourage investors and others to review our financial information in its entirety and not rely on a single financial measure.

**Safe Harbor Statement**

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the recognition of the Company's Amazfit-branded products; the Company's growth strategies; trends and competition in global wearable technology market; changes in the Company's revenues and certain cost or expense accounting policies; governmental policies relating to the Company's industry and general economic conditions around the globe. Further information regarding these and other risks is included in the Company's filings with the United States Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

**For investor and media inquiries, please contact:**

In China:

Zepp Health Corporation

Grace Yujia Zhang

Email: ir@zepp.com

Piacente Financial Communications

Tel: +86-10-6508-0677

Email: zepp@tpg-ir.com

**Zepp Health Corporation**

**UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS** 

**(Amounts in thousands of U.S. dollars ("US$")**

**except for number of shares and per share data, or otherwise noted)**

---

| | | |
|:---|:---|:---|
|  | **As of December 31,** | **As of June 30,** |
|  | **2024** | **2025** |
|  | **US$** | **US$** |
| **Assets** |  |  |
| **Current assets:** |  |  |
| Cash and cash equivalents | 91069 | 55445 |
| Restricted cash | 19666 | 39875 |
| Accounts receivable, net | 62965 | 70916 |
| Amounts due from related parties | 2663 | 3661 |
| Inventories, net | 56789 | 79911 |
| Short-term investments | 997 | 1015 |
| Prepaid expenses and other current assets | 17415 | 21615 |
| **Total current assets** | **251564** | **272438** |
| Property, plant and equipment, net | 6898 | 6161 |
| Intangible asset, net | 7091 | 14352 |
| Goodwill | 9581 | 9581 |
| Long-term investments | 225910 | 218970 |
| Deferred tax assets | 17465 | 17666 |
| Amount due from related parties, non-current | 2019 | 2051 |
| Other non-current assets | 4607 | 4693 |
| Operating lease right-of-use assets | 3458 | 3059 |
| **Total assets** | **528593** | **548971** |

---

**Zepp Health Corporation**

**UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - CONTINUED**

**(Amounts in thousands of U.S. dollars ("US$")**

**except for number of shares and per share data, or otherwise noted)**

---

| | | |
|:---|:---|:---|
|  | **As of December 31,** | **As of June 30,** |
|  | **2024** | **2025** |
|  | **US$** | **US$** |
| **Liabilities** |  |  |
| **Current liabilities:** |  |  |
| Accounts payable | 51077 | 86517 |
| Advance from customers | 197 | 250 |
| Amount due to related parties | 2477 | 531 |
| Accrued expenses and other current liabilities | 37576 | 38847 |
| Income tax payables | 508 | 508 |
| Notes payable | 61679 | 86623 |
| Short-term bank borrowings | 41853 | 35038 |
| **Total current liabilities** | **195367** | **248314** |
| Deferred tax liabilities | 3117 | 3143 |
| Long-term borrowings | 75241 | 70403 |
| Other non-current liabilities | 133 | 136 |
| Non-current operating lease liabilities | 2007 | 1585 |
| **Total liabilities** | **275865** | **323581** |

---

**Zepp Health Corporation**

**UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - CONTINUED**

**(Amounts in thousands of U.S. dollars ("US$")**

**except for number of shares and per share data, or otherwise noted)**

---

| | | |
|:---|:---|:---|
|  | **As of December 31,** | **As of June 30,** |
|  | **2024** | **2025** |
|  | **US$** | **US$** |
| **Equity** |  |  |
| Ordinary shares | 26 | 26 |
| Additional paid-in capital | 278116 | 279258 |
| Treasury stock | (14993) | (16045) |
| Accumulated retained earnings | 28618 | 1137 |
| Accumulated other comprehensive loss | (40178) | (38986) |
| **Total Zepp Health Corporation shareholders' equity** | **251589** | **225390** |
| Noncontrolling interest | 1139 | - |
| **Total equity** | **252728** | **225390** |
| **Total liabilities and equity** | **528593** | **548971** |

---

**Zepp Health Corporation**

**UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

**(Amounts in thousands of U.S. dollars ("US$")**

**except for number of shares and per share data, or otherwise noted)**

---

| | | |
|:---|:---|:---|
|  | **For the Three Months Ended June 30,** | **For the Three Months Ended June 30,** |
|  | **2024** | **2025** |
|  | **US$** | **US$** |
| Revenues | 40642 | 59406 |
| Cost of revenues | (24281) | (37915) |
| **Gross profit** | **16361** | **21491** |
| **Operating expenses:** |  |  |
| Selling and marketing | (10555) | (12050) |
| General and administrative | (4853) | (4384) |
| Research and development | (10818) | (11157) |
| **Total operating expenses** | **(26226)** | **(27591)** |
| **Operating loss** | **(9865)** | **(6100)** |
| **Other income and expenses:** |  |  |
| Interest income | 948 | 295 |
| Interest expense | (1373) | (1245) |
| Other income/(expense), net | 127 | 56 |
| Gain/(loss) from fair value change of long-term investments | (300) | 3 |
| **Loss before income tax and loss from equity method investments** | **(10463)** | **(6991)** |
| Income tax expenses | (47) | (242) |
| **Loss before loss from equity method investments** | **(10510)** | **(7233)** |
| Net loss from equity method investments | (337) | (507) |
| **Net loss** | **(10847)** | **(7740)** |
| Less: Net loss attributable to noncontrolling interest | (10) | - |
| **Net loss attributable to Zepp Health Corporation** | **(10837)** | **(7740)** |
| **Basic and diluted net loss per share attributable to Zepp Health Corporation** | (0.04) | (0.03) |
| **Basic and diluted net loss per ADS (16 ordinary shares equal to 1 ADS)** | (0.67) | (0.49) |
| **Weighted average number of shares used in computing basic and diluted net loss per share** | 260399926 | 253536783 |

---

**Zepp Health Corporation**

**Reconciliation of GAAP and Non-GAAP Results**

**(Amounts in thousands of U.S. dollars ("US$")**

**except for number of shares and per share data, or otherwise noted)**

---

| | | |
|:---|:---|:---|
|  | **For the Three Months Ended June 30,** | **For the Three Months Ended June 30,** |
|  | **2024** | **2025** |
|  | **US$** | **US$** |
| **Total operating expenses** | **(26226)** | **(27591)** |
| Share-based compensation expenses | 906 | 482 |
| Amortization of intangible assets resulting from acquisitions and business cooperation agreements | 565 | 711 |
| **Total adjusted operating expenses** | **(24755)** | **(26398)** |
| **Operating loss** | **(9865)** | **(6100)** |
| Share-based compensation expenses | 906 | 482 |
| Amortization of intangible assets resulting from acquisitions and business cooperation agreements | 565 | 711 |
| **Adjusted operating loss** | **(8394)** | **(4907)** |
| **Net loss** | **(10847)** | **(7740)** |
| Share-based compensation expenses | 906 | 482 |
| Amortization of intangible assets resulting from acquisitions and business cooperation agreements | 565 | 711 |
| (Gain)/loss from fair value change of long-term investments | 300 | (3) |
| Loss from equity method investments | 337 | 507 |
| Income tax expenses | 47 | 242 |
| Interest income | (948) | (295) |
| Interest expense | 1373 | 1245 |
| **Adjusted EBIT<sup>4</sup>** | **(8267)** | **(4851)** |
| **Net loss attributable to Zepp Health Corporation** | **(10837)** | **(7740)** |
| Share-based compensation expenses | 906 | 482 |
| Amortization of intangible assets resulting from acquisitions and business cooperation agreements | 565 | 711 |
| (Gain)/loss from fair value change of long-term investments | 300 | (3) |
| Loss from equity method investments | 337 | 507 |
| Tax effects on non-GAAP adjustments | (91) | (116) |
| **Adjusted net loss attributable to Zepp Health Corporation** | **(8820)** | **(6159)** |
| **Adjusted basic and diluted net loss per share attributable to Zepp Health Corporation<sup>5</sup>** | (0.03) | (0.02) |
| **Adjusted basic and diluted net loss per ADS (16 ordinary shares equal to 1 ADS)** | (0.54) | (0.39) |
| **Weighted average number of shares used in computing adjusted basic and diluted net loss per share** | 260399926 | 253536783 |
| **Share-based compensation expenses included are follows:** |  |  |
| Selling and marketing | 87 | 3 |
| General and administrative | 412 | 289 |
| Research and development | 407 | 190 |
| **Total** | **906** | **482** |

---

<sup>4</sup> Adjusted EBIT is a non-GAAP financial measure, which is defined as net loss, excluding (i) share-based compensation expenses, (ii) amortization of intangible assets resulting from acquisitions and business cooperation agreements, (iii) gain/(loss) from fair value change of long-term investment, (iv) impairment loss from long-term investments, (v) income/(loss) from equity method investments, (vi) income tax (benefit)/ expense, and (vii) interest income and interest expense.

<sup>5</sup> Adjusted diluted net income/(loss) is the abbreviation of adjusted net (loss)/income attributable to Zepp Health Corporation, which is a non-GAAP measure and excludes (i) share-based compensation expenses, (ii) amortization of intangible assets resulting from acquisitions and business cooperation agreements, (iii) gain/(loss) from fair value change of long-term investment, (iv) impairment loss from long-term investments, and (v) income/(loss) from equity method investments, and (vi) tax effects of the above non-GAAP adjustments, and is used as the numerator in computation of adjusted basic and diluted net loss per ADS attributable to Zepp Health Corporation.

**Zepp Health Corporation**

**UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

**(Amounts in thousands of U.S. dollars ("US$")**

**except for number of shares and per share data, or otherwise noted)**

---

| | | |
|:---|:---|:---|
|  | **For the Six Months Ended June 30,** | **For the Six Months Ended June 30,** |
|  | **2024** | **2025** |
|  | **US$** | **US$** |
| Revenues | 80599 | 97943 |
| Cost of revenues | (49538) | (62091) |
| **Gross profit** | **31061** | **35852** |
| **Operating expenses:** |  |  |
| Selling and marketing | (21324) | (25891) |
| General and administrative | (11273) | (10902) |
| Research and development | (24239) | (23534) |
| **Total operating expenses** | **(56836)** | **(60327)** |
| **Operating loss** | **(25775)** | **(24475)** |
| **Other income and expenses:** |  |  |
| Interest income | 1960 | 876 |
| Interest expense | (2816) | (2603) |
| Other income/(expense), net | 195 | 60 |
| Gain/(loss) from fair value change of long-term investments | 1803 | (122) |
| **Loss before income tax and loss from equity method investments** | **(24633)** | **(26264)** |
| Income tax expenses | (119) | (352) |
| **Loss before loss from equity method investments** | **(24752)** | **(26616)** |
| Net loss from equity method investments | (896) | (865) |
| **Net loss** | **(25648)** | **(27481)** |
| Less: Net loss attributable to noncontrolling interest | (42) | - |
| **Net loss attributable to Zepp Health Corporation** | **(25606)** | **(27481)** |
| **Basic and diluted net loss per share attributable to Zepp Health Corporation** | (0.10) | (0.11) |
| **Basic and diluted net loss per ADS (16 ordinary shares equal to 1 ADS)** | (1.58) | (1.72) |
| **Weighted average number of shares used in computing basic and diluted net loss per share** | 259962803 | 254965539 |

---

**Zepp Health Corporation**

**Reconciliation of GAAP and Non-GAAP Results**

**(Amounts in thousands of U.S. dollars ("US$")**

**except for number of shares and per share data, or otherwise noted)**

---

| | | |
|:---|:---|:---|
|  | **For the Six Months Ended June 30,** | **For the Six Months Ended June 30,** |
|  | **2024** | **2025** |
|  | **US$** | **US$** |
| **Total operating expenses** | **(56836)** | **(60327)** |
| Share-based compensation expenses | 3189 | 1071 |
| Amortization of intangible assets resulting from acquisitions and business cooperation agreements | 1132 | 1346 |
| **Total adjusted operating expenses** | **(52515)** | **(57910)** |
| **Operating loss** | **(25775)** | **(24475)** |
| Share-based compensation expenses | 3189 | 1071 |
| Amortization of intangible assets resulting from acquisitions and business cooperation agreements | 1132 | 1346 |
| **Adjusted operating loss** | **(21454)** | **(22058)** |
| **Net loss** | **(25648)** | **(27481)** |
| Share-based compensation expenses | 3189 | 1071 |
| Amortization of intangible assets resulting from acquisitions and business cooperation agreements | 1132 | 1346 |
| (Gain)/loss from fair value change of long-term investments | (1803) | 122 |
| Loss from equity method investments | 896 | 865 |
| Income tax expenses | 119 | 352 |
| Interest income | (1960) | (876) |
| Interest expense | 2816 | 2603 |
| **Adjusted EBIT** | **(21259)** | **(21998)** |
| **Net loss attributable to Zepp Health Corporation** | **(25606)** | **(27481)** |
| Share-based compensation expenses | 3189 | 1071 |
| Amortization of intangible assets resulting from acquisitions and business cooperation agreements | 1132 | 1346 |
| (Gain)/loss from fair value change of long-term investments | (1803) | 122 |
| Loss from equity method investments | 896 | 865 |
| Tax effects on non-GAAP adjustments | (182) | (219) |
| **Adjusted net loss attributable to Zepp Health Corporation** | **(22374)** | **(24296)** |
| **Adjusted basic and diluted net loss per share attributable to Zepp Health Corporation** | (0.09) | (0.10) |
| **Adjusted basic and diluted net loss per ADS (16 ordinary shares equal to 1 ADS)** | (1.38) | (1.52) |
| **Weighted average number of shares used in computing adjusted basic and diluted net loss per share** | 259962803 | 254965539 |
| **Share-based compensation expenses included are follows:** |  |  |
| Selling and marketing | 337 | 45 |
| General and administrative | 1472 | 575 |
| Research and development | 1380 | 451 |
| **Total** | **3189** | **1071** |

---